All Stories

  1. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: A multicentre study
  2. Ultrasound-guided ablation for hepatocellular carcinoma: time for a reappraisal?
  3. Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C
  4. Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C
  5. European Association for the Study of the Liver Hepatocellular Carcinoma summit 2014: old questions, new (or few) answers?
  6. Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma
  7. Transarterial chemoembolization and sorafenib in hepatocellular carcinoma
  8. Focal lesions in cirrhotic liver: what else beyond hepatocellular carcinoma?
  9. EASL HCC summit: liver cancer management
  10. Body Mass Index and Liver Stiffness Affect Accuracy of Ultrasonography in Detecting Steatosis in Patients With Chronic Hepatitis C Virus Genotype 1 Infection
  11. Determinants of alpha‐fetoprotein levels in patients with hepatocellular carcinoma: Implications for its clinical use
  12. Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C
  13. O123 POST SORAFENIB SURVIVAL IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: THE ROLE OF TUMOR PROGRESSION AND LIVER IMPAIRMENT
  14. P1009 THE HISTOLOGICAL OR ULTRASONOGRAPHIC DETECTION OF STEATOSIS AFFECTS THE PERFORMANCE OF LIVER STIFFNESS MEASUREMENT FOR FIBROSIS ASSESSMENT IN PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION
  15. P965 PERSONALIZED THERAPY WITH SORAFENIB FOR HEPATOCELLULAR CARCINOMA
  16. Post sorafenib survival in patients with advanced hepatocellular carcinoma: The role of tumor progression and liver impairment
  17. The histological or ultrasonographic detection of steatosis affects the performance of LSM in patients with chronic HCV genotype 1 infection
  18. Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results
  19. Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age?
  20. Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C
  21. Rs4374383 single nucleotide polymorphism of MERTK gene influences the development of hepatocellular carcinoma (HCC) in patients with HCV cirrhosis
  22. Personalized sorafenib therapy for hepatocellular carcinoma
  23. Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C
  24. Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C
  25. NT Pro BNP Plasma Level and Atrial Volume Are Linked to the Severity of Liver Cirrhosis
  26. Survival of Patients with Hepatocellular Carcinoma (HCC) Treated by Percutaneous Radio-Frequency Ablation (RFA) Is Affected by Complete Radiological Response
  27. Rise and fall of HCV‐related hepatocellular carcinoma in Italy: a long‐term survey from the ITA.LI.CA centres
  28. Assessment of treatment response in hepatocellular carcinoma: a review of the literature
  29. Faculty Opinions recommendation of Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: results of an Italian field practice multicenter study.
  30. Treatment of hepatocellular carcinoma: present and future
  31. 262 SURVIVAL OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) IS AFFECTED BY COMPLETE RESPONSE TO RADIO-FREQUENCY THERMAL ABLATION (RFTA)
  32. Faculty Opinions recommendation of Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study.
  33. Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma
  34. T-38 Survival of patients with hepatocellular carcinoma (HCC) is affected by complete response to radio-frequency thermal ablation (RFTA)
  35. Faculty Opinions recommendation of Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection.
  36. Causes of and Prevention Strategies for Hepatocellular Carcinoma
  37. Faculty Opinions recommendation of Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease.
  38. Imaging findings of liver resection using a bipolar radiofrequency electrosurgical device—Initial observations
  39. Letter: liver dysfunction and survival in hepatocellular carcinoma treated by transarterial chemoembolisation – authors’ reply
  40. CS.01.3 THE EMERGING IMPACT OF HCC-NAFLD IN ITALY
  41. OC-26 The emerging impact of HCC-NAFLD in Italy
  42. Faculty Opinions recommendation of Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.
  43. Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study
  44. Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy
  45. Should cirrhosis change our attitude towards treating non‐hepatic cancer?
  46. Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation
  47. OC-1 Prospective Italian multicenter field-practice study with sorafenib for advanced hepatocellular carcinoma
  48. Update on new approaches in the management of hepatocellular carcinoma
  49. Cost analysis of recall strategies for non-invasive diagnosis of small hepatocellular carcinoma
  50. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma
  51. Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: A meta-analysis
  52. Cost-effectiveness of recall strategies for non-invasive diagnosis of small hepatocellular carcinoma
  53. 811 COST-EFFECTIVENESS OF RECALL STRATEGIES FOR NON-INVASIVE DIAGNOSIS OF SMALL HEPATOCELLULAR CARCINOMA
  54. 778 SURVIVAL OF UNRESECTABLE HEPATOCELLULAR CARCINOMA: A META-ANALYSIS OF THE CONTROL ARMS OF 28 RANDOMIZED TRIALS
  55. Prognostic scores for hepatocellular carcinoma: none is the winner
  56. Survival of unresectable hepatocellular carcinoma: A meta-analysis of the control arms of 28 randomized trials
  57. Multimodal approaches to the treatment of hepatocellular carcinoma
  58. Needle track seeding following percutaneous procedures for hepatocellular carcinoma
  59. Hepatocellular Cancer: Optimal Strategies for Screening and Surveillance
  60. Meta-Analysis of the Placebo Rates of Clinical Relapse and Severe Endoscopic Recurrence in Postoperative Crohn's Disease
  61. Can Chemotherapy Concurrently Delivered to Radiotherapy Improve the Results of Radiotherapy as (Neo-) adjuvant Therapy in Rectal Cancer? A Systematic Review and Meta-analysis
  62. Seeding after radiofrequency ablation of hepatocellular carcinoma in patients with cirrhosis: A prospective study
  63. Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems
  64. Long-Term Course of Chronic Hepatitis C in Children: From Viral Clearance to End-Stage Liver Disease
  65. The impact of radiotherapy on survival in resectable gastric carcinoma: A meta-analysis of literature data
  66. [257] MORTALITY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA PREDICTED BY SIX SCORING SYSTEMS: NONE IS THE WINNER
  67. Mortality in patients with hepatocellular carcinoma predicted by six scoring systems: None is the winner